Author:
Gong Xubo,Zhang Yi,He Xin,Moloudizargari Milad,Yu Teng,Wang Lin,Liu Weiwei,Jin Lan,Xu Huiying,Xu Yang,Tao Zhihua,Qian Wenbin
Abstract
AbstractVenetoclax (VEN), the first selective Bcl-2 inhibitor, has shown efficacy and safety both as monotherapy and in combination with other agents in the treatment of newly diagnosed acute myeloid leukemia (AML), while its role in relapsed or refractory (R/R) disease is not well defined. Here, we reviewed the latest advances of VEN-based therapy for R/R AML from the 2022 American Society of Hematology (ASH) Annual Meeting, including some novel and encouraging regimes, such as VCA, VAH, and HAM regimes, etc. Further research is still needed to fully understand the optimal use of these agents in R/R AML treatment.
Funder
National Natural Science Foundation of China
Zhejiang Medical and Health Science and Technology Project
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology